Else Marit Inderberg

Oslo University Hospital

Dr. Else Marit Inderberg has 17 years of experience in immunomonitoring of clinical trials, currently overseeing immunomonitoring of 15 ongoing clinical studies, both academic and industry sponsored. She is group leader at the Translational Research Unit who houses two groups (other PI Dr S. Wälchli). Her group is working on TCR and has, with clinical collaboration, initiated the first Scandinavian academically run clinical TCR protocol (NCT03431311, clinicaltrials.gov) with one patient who has completed treatment. The main research focus is on T-cell function and specificity, tumour microenvironment, and the identification of predictive biomarkers of clinical and immunological response to cancer therapy. The lab has expertise in analysing T-cell responses in clinical studies, immune cell phenotyping, cytokine production (Flow cytometry, ELISPOT, BioPlex) and target cell killing using high-throughput technologies such as mass cytometry (CyTOF, Hyperion) and live-cell imaging. Google Scholar

Sébastien Wälchli

Oslo University Hospital

Sébastien Wälchli co-leads the translational research lab at the section for Cellular therapy, OUS, a newly established pre-clinical entity directly connected to the immunomonitoring unit. Sébastien Wälchli leads the molecular biology of the T-cell receptor (TCR) and the Chimeric Antigen Receptor (CAR) development platforms. The TCR platform has led to the filling of numerous patents, the establishment of a biotech (Zelluna Immuntherapy AS, 2016) and the first TCR tested in human in Norway (ClinicalTrials.gov Identifier: NCT03431311). The CAR platform has completed the pre-clinical development of 2 candidates and is working on around 15 new constructs, most of them directed against solid tumours. Advanced universal therapeutic solutions are also in our pipeline (3 patents), and different innovative tools in the immunotherapeutic field (vaccination, effector cell improvement, etc.). Google Scholar

Einar Vik-Mo

Oslo University Hospital

Central nervous system malignancies accounts for 1% of all adult cancers. The most common primary brain neoplasm is a glioma, which accounts for approximately half of all intracranial neoplasms. In patients with glioblastoma multiforme, the most malignant of gliomas, median survival has remained 9 to 12 months for decades. The treatment of gliomas is based on surgical resection, but this is inadequate. The reason for this shortcoming has been hypothesized to be a result of tumour infiltration into healthy tissue, thus making it non resectable. Adjuvant radio- and chemotherapy may prolong the patients life, but eventually most patients relapse. For nearly one hundred years, glia cells were thought to be the only dividing cells in the postnatal brain, thus, making them the candidates susceptible to malignant transformation. As the concept of neuronal stem cells emerges, the cellular antecedent of gliomas is being once again reviewed in the light of this new evidence. As stem cells already have the machinery necessary for self-renewal, fewer mutagenic events may be necessary for tumourigenic transformation than in differentiated cells. Neural stem cells also exhibit properties similar to tumour cells, i.e. high motility, diversity of progeny, robust proliferative potential, association with blood vessels and white-matter tracts and an immature expression profile. Prospective isolation of tumour initiating cells is possible using tumour specific antigens. We are currently working on the isolation and characterization of such tumour initiating cells using primary cell cultures, both as floating neurosphere assays and adherent cultures, and combining this with FACS and MACS to prospectively isolate the putative tumour initiating cells. Google Scholar

Nadia Mensali

Oslo University Hospital

Post Doctoral Research Associate, Department of Cellular Therapy, Oslo University Hospital, The Radiumhospital. Google Scholar

Marcos J. Araúzo Bravo

Biogipuzkoa Health Research Institute

Graduated as an electronic and control engineer from the University of Valladolid, Spain. In 2001 he earned a Ph.D. in Industrial Technologies from the University of Cartagena, developing neuro-fuzzy algorithms for monitoring penicillin production. From 1998 to 2004 he was an Associate Professor in electrical engineering at Burgos University. In 2000 he received a scholarship from the Japanese Ministry of Education to work in the field of metabolic engineering at Kyushu Institute of Technology, Japan. In 2002 he earned a Ph.D. in information technology and biotechnology from the Kyushu Institute of Technology (KIT), Iizuka, Japan. From 2004 to 2006 he was a Japan-Society-for-the-Promotion-of-Science (JSPS) postdoctoral research fellow at the Kyushu Institute of Technology, where he worked on the synergetic control of genetic networks through transcriptional regulators. Since 2006 he leads the laboratory of Computational Biology and Bioinformatics at the Max Planck Institute for Molecular Biomedicine in Münster, Germany, developing tools for deciphering cellular reprogramming, methods to study transcription regulation, and algorithms for high-throughput data analysis. Since 2014 he is an Ikerbasque Research Professor, head of the group of Computational Biology and Systems Biomedicine at the Biodonostia Health Research Institute, San Sebastián, Spain. Since 2019 Member of the CIBER network of Frailty and Healthy Ageing (CIBERfes) (Instituto de Salud Carlos III), Madrid, Spain. Since 2019 Member of the Thematic Network of Excellence for Transitional Bioinformatics (TransBioNet) RED2018-102404-T, Barcelona Supercomputing Center, Spain. Guest Scientist at the Max Planck Institute for Molecular Biomedicine in Münster, Germany. Coordinator of the European project 4D-HEALING: Data-Driven Drug Discovery for Wound Healing of the ERA-Net Collaboration on Systems Medicine (ERACoSysMed) JTC-2 (H2020) call 2017. PI of the European project CIRCULAR VISION: Circular DNA in diagnosis and disease models of the Future and Emerging Technologies (FET) call. PI of the European project IPerGlio: Improving personalised glioblastoma care by intertwined immunomics and artificial intelligence approaches of the ERAPerMed JTC2022 call. Since 2022 Academic Collaborator of Research of the Department of Cellular Biology and Histology of the University of the Basque Country UPV/EHU, Spain. He develops Big Data approaches for integrating omics, image and clinical history data to study the interaction of biological networks in terms of their topology, dynamics, and perturbations to interpret complex biological systems associated with neurodegenerative diseases, cancer, ageing, stem cells and regenerative medicine. Google Scholar

Daniela Gerovska

Biogipuzkoa Health Research Institute

Dr Gerovska is an expert in omics, microarray, NGS and single cell data processing. Engineer Geophysicist and Environmental Engineer from the University of Mining and Geology, Sofia, Bulgaria (1995). TEMPUS exchange student in the University of Nottingham, UK (1992-93). Doctor of Geophysics from the University of Mining and Geology, Sofia, Bulgaria (2003), and Doctor of Engineering from the University of Kyushu, Fukuoka, Japan (2004). With over 20 years of experience in environmental geophysics and mineral prospecting in Japan and Canada, combining field work with Big Data image analysis. Expert in the processing and analysis of Big Data sets, in Matlab and Python in Linux and Windows environments. Worked for 2 years as a Postdoctoral Fellow in Geomagnetism at the University of Edinburgh, UK, implementing software for modeling the magnetic field of the Earth's lithosphere from satellite data. With over 10 publications as the first and corresponding author in the field of potential field geophysics in journals such as Geophysics (Gerovska and Araúzo-Bravo, 2006; Stavrev et al., 2006; Gerovska et al., 2010; Gerovska et al., 2010),  and more than 32 publications in the areas of biomedicine and bioinformatics. Principal Investigator of 5 RIS3 projects of the Department of Health of the Basque Government, Spain and two projects of the Support Program for the Guipuzcoan Network of Science, Technology and Innovation, Spain. Participates in the EU project H2020 Future and Emerging Technologies FET “CIRCULAR VISION: Circular DNA in diagnosis and disease models”; in the ERAPerMed Joint Transnational Call 2022 PREVENTION IN Personalised Medicine project IPerGlio: Improving personalised glioblastoma care by intertwined immunomics and artificial intelligence approaches; And in the European project H2020 of the Call ERACoSysMed – Systems Medicine to address clinical needs “4D-HEALING: Data-Driven Drug Discovery for Wound Healing”. Participates in multiple Spanish national projects such as MINECO, Fundacion Mutua Madrileña, RIS3, ELKARTEK, HAZITEK. Google Scholar

Roberto Pallini

Fondazione Policlinico Universitario Agostino Gemelli IRCCS (FPG)

R. Pallini is Associated Professor at the Neurosurgery Institute of the Catholic University of Medicine in Rome and a Neurosurgeon at Fondazione Policlinico Universitario A. Gemelli IRCCS. He graduated with honor in Medicine and Surgery at the “Sacro Cuore” Catholic University of Rome in July 1981. In 1986, he got the Specialization in Neurosurgery with honor and the Ph.D. in Neurosurgery. Prof. G. Rossi and Prof. G. Maira have been tutors of R. Pallini during his professional development that concluded at the Karolinska Hospital of Stockholm and at the Presbyterian University Hospital of Pittsburgh, USA. His long professional activity includes 2.500 surgeries on patients affected by glioblastoma or glioma before anti‐cancer (glioblastoma, glioma) treatments or on patients afflicted by meningioma, neurinoma or chordoma. Pallini contributed to the Center of Regenerative Research of the Nervous System establishment at the Catholic University as Scientific Coordinator and Scientific Director. He has great research experience in brain cancers, glioblastoma cancer stem cells, personalized medicine, tumor angiogenesis, skull base tumors and anti‐cancer as well as regenerative therapies with stem cells. In the last five years, R. Pallini has been coordinator of an AIRC IG project (2019, Id23154) and a RF project (2019, 12368786). Google Scholar

Gabriele Lucia

Istituto Superiore di Sanità (ISS)

Lucia Gabriele is Head of Tumor Immunology Section at ISS (Rome), and Co-Chair of Vaccine, Inflammation and Immunomonitoring Platform (EATRIS-ERIC). After her PhD in Genetics (Sapienza University, Rome), she was fellow in the Laboratory of Immunopathology, NIAID, NIH, USA. She performed many studies on immunity, with special focus on IFN signaling, in cancer and infectious diseases. Her seminal papers have contributed to uncover key aspects of the development and function of dendritic cells. Her research has also focused on the development of novel DC‐ based immunotherapies for cancer patients, on cancer-immune system crosstalk and on the immune mechanisms underneath the effects of epigenetic and immunomodulatory drugs. Currently, in close collaboration with clinical centres (Sapienza University, IDI-IRCCS, Catholic University, Spallanzani-IRCCS; Rome), she is promoting research studies for the discovery of immune markers in diverse types of cancer (melanoma, GBM) and infectious diseases (COVID-19, Tuberculosis). Her group has 30 year-long experience in phenotypic and functional immune characterization, high-throughput profiling of human immune cells and immunological assays. She has been PI or Unit PI of European and national grants, and author of peer-reviewed papers as first, last, and corresponding author (H- Index 34). Major Positions and education: 2018‐present: Head of Immuno‐Oncology Section, Dept. OMM, ISS, Rome, Italy; 2017‐present: Co‐chair of Vaccines Product Platform, EATRIS‐ERIC, Amsterdam, Netherlands; 2002‐2018: Group Leader, Dept. of OMM, ISS, Rome, Italy; 1999‐2000: Special volunteer/UICC‐TCRF fellow, Laboratory of Immunopathology (LIP), NIAID, NIH, Bethesda, USA; 1994‐1998: Visiting Fellow/Special volunteer, LIP, NIAID, NIH, Bethesda, USA; 01/01/1994: PhD in Genetics, University of Rome “La Sapienza”; 01/01/1989: Bachelor of Biology, University of Rome “La Sapienza”. Google Scholar

Quintino Giorgio Dalessandris

Fondazione Policlinico Universitario Agostino Gemelli IRCCS (FPG)

Tumor AngiogenesisTumorsTumor BiologyCancer BiomarkersPrognostic MarkersMolecular OncologyClinical OncologyExperimental OncologyTranslational MedicineNeuro-OncologyNeurosurgeryPeripheral Nerve SurgeryMeningiomaGlioblastoma Multiforme (GBM)Traumatic Brain InjuryStem Cell DifferentiationProtein ExpressionNeural Stem CellsEndothelial CellsHydrocephalusAngiogenesisNeuroradiologyMedulloblastoma Google Scholar

Antonio Cosma

Luxembourg Institute of Health (LIH)

Dr. Cosma graduated in biological science at the “Università degli Studi di Milano” (Italy) and obtained his PhD in Human Biology at the Faculty of Medicine of the Ludwig-Maximilians-Universität (Germany). In 2015, he obtained the Accreditation to Direct Research from the “Université Paris-Sud” (France). From 2009 to 2018, he was the head of the FlowCyTech core facility at the Atomic Energy Commission (Fontenay-aux-Roses, France) and is now the head of the Biospecimen Services and Data Generation Unit at the LIH. The unit hosts the major processing facilities of the institute and in particular the National Cytometry Platform (NCP). His scientific activity focused for a long time on the study of the immune system during HIV infection. In 2011, he was leading the first core facility in Europe to implement the mass cytometry. Mass cytometry (or Cytometry by Time Of Flight: CyTOF) combines flow cytometry and mass spectrometry to achieve the simultaneous single cell measurement of more than 50 markers (commonly proteins). He used the CyTOF for the comparative analysis of the immune system in humans and in the Cynomolgus macaque model, and the characterization of the innate immune system in infectious diseases, vaccination models and inflammatory diseases. At present, he is implementing several projects making use of single cell technologies to compare the immune system in different diseases. He is an expert in the development of flow-cytometry-based assays, data management and analysis. He is working to facilitate multidimensional data analysis by merging the fields of flow cytometry and Business Intelligence. He recently proposed a new method for the annotation of cell type based on prime numbers and the fundamental theorem of arithmetic. Antonio Cosma is very active in the single cell community in organizing workshops and trainings. He is an Associate Editor for the journal Cytometry A. Google Scholar

Lyazid Drissi Yahyaoui

Luxembourg Institute of Health (LIH)

Lyazid Drissi Yahyaoui is PhD Student at National Cytometry Platform Luxembourg Institute of Health (LIH). FNR - Fonds National de la Recherche Project: Research rue Henri Koch, 29 4354 Esch-Sur-Alzette Luxembourg

Fanny Hedin

Luxembourg Institute of Health (LIH)

Fanny Hedin Engineer in Flow Cytometry. Optimized Multicolor Immunofluorescence Panel (OMIP) Database. National Cytometry Platform - Luxembourg Institute of Health

Ruben Andreas Sakowsky

Dept. of Medical Ethics and History of Medicine, University Medical Centre Goettingen (UMG)

Dr. Sakowsky is a post-doctoral research fellow at UMG and specialises in deliberative theory and methodology, citizen and stakeholder participation, and health preference elicitation. In early 2020, he received his PhD in Health Economics from Aberdeen University, where he worked on prospective patients’ attitudes towards breast cancer screening and on citizens’ preferences for pandemic mitigation strategies. He contributed to, and led, the organisation of citizens’ juries on breast cancer screening in Sydney, Australia, and on privacy concerns and benefits of pandemic apps as well as on GPS-tracking for people with dementia in Göttingen, Germany. Currently he is working on a project funded by the Lower Saxony Ministry of Science and Culture to translate citizen jury methodology into the digital realm, as well as on a project to leverage digital communication technology for increased stakeholder participation in health care funded by the German Ministry of Education and Research. He is a member of the working group on digitalisation in health at the German Academy for Ethics in Medicine and of the study group “Making Science Better: Ethical and Epistemic Norms for Responsible Research in the 21st Century” at the Hanse Institute for Advanced Studies in Delmenhorst. At UMG, he is embedded in a team with considerable expertise on citizen and stakeholder participation as well as on the ethics of Artificial Intelligence and data usage. His team leader Prof. Dr. Schicktanz, with whom he will jointly work on WP6, is an internationally recognized expert on patient and stakeholder participation. In 2001, she was the project coordinator of the first nation-wide citizens’ conference on genetic testing. Since then, she has organized, scientifically examined, and evaluated several types of patient and stakeholder engagement events, covering a wide spectrum of participatory methodologies, ranging from patient hearing workshops, focus groups with patients and stakeholders, stakeholder consensus conferences, and citizen involvement via surveys. PubMed

Simone Krieger

Dept. of Medical Ethics and History of Medicine, University Medical Centre Goettingen (UMG)

Dr. rer. medic. Simone Krieger Dipl.-Psychologin - Psychologist Wissenschaftliche Mitarbeiterin – Research Associate. Universittätsmedizin - University Medical Center Göttigen. Institut für Ethik und Geschichte der Medizin – Dept. of Medical Ethics and History of Medicine. Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie. Von-Siebold-Str. 3, 37075 Göttingen.

Amirali Jahani Yazdi

Dept. of Medical Ethics and History of Medicine, University Medical Centre Goettingen (UMG)

Dr. rer. medic. Amirali Jahani Yazdi has been working as a German teacher for 4 years and have a German certificate at level C2 (CFER) with the best grade from Halle University. He is very familiar with digital teaching tools because I have private students from different countries and I teach online. He has also taught many different books such as StartenWir!, DAF Kompakt or People, among others, and not just these books and normal courses, but preparation courses for the exams from A1 to C2 and their books such as exam training, station C1 and final station C2, among others. Research Assistant, University Medical Center Göttingen. Dept. of Medical Ethics and History of Medicine. Humboldtallee 36. 37073 Göttingen (Germany). Research Assistant, University Medical Center Göttingen. Dept. of Medical Ethics and History of Medicine. Humboldtallee 36. 37073 Göttingen (Germany). Google Scholar

powered by Free-Counters.org